FDA Biosimilars Meeting Seeks Input On Product Naming, Foreign Data And Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Two-day public hearing in November will cover nearly all aspects of the new pathway except the patent challenge mechanism.